PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.

Evidence

Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris.

PUBLICATION: Transl Oncol. 2019 Sep 9;12(12):1557-1565. doi: 10.1016/j.tranon.2019.08.008. AUTHORS: Slembrouck L., Darrigues L., Laurent C., Mittempergher L., Delahaye L.J., Vanden Bempt I., Vander Borght S., Vliegen L., Sintubin P., Raynal V., Bohec M., Reyes C., Rapinat A., Helsmoortel C., Jongen L., Hoste G., Neven P., Wildiers H., Smeets A., Nevelsteen Read More

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology

PUBLICATION: Journal of Molecular Diagnostics September 2019 Volume 21, Issue 5, Pages 808–823. AUTHORS: Lorenza Mittempergher, Leonie J.M.J. Delahaye, Anke T. Witteveen, Jacob B. Spangler, Fariet Hassenmahomed, Sammy Mee, Soufiane Mahmoudi, Jiang Chen, Simon Bao, Mireille H.J. Snel, Sandra Leidelmeijer, Naomi Besseling, Anne Bergstrom Lucas, Carlos Pabón-Peña, Sabine C. Linn, Read More

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline

PUBLICATION: Journal of Clinical Oncology 37, no. 22 (August 01, 2019) 1965-1977. DOI: 10.1200/JCO.19.00948. AUTHORS: N. Lynn Henry, MD, PhD; Mark R. Somerfield, PhD; Vandana G. Abramson, MD; Nofisat Ismaila, MD; Kimberly H. Allison, MD; Carey K. Anders, MD; Diana T. Chingos, MS, MFA; Andrea Eisen, MD; Bruno L. Ferrari, Read More

The Changing Role of Gene-Expression Profiling in the Era of Deescalating Adjuvant Chemotherapy in Early-Stage Breast Cancer

PUBLICATION: Ann Surg Oncol (2019) 26: 3495. https://doi.org/10.1245/s10434-019-07511-8. AUTHORS: J.E.C. van Steenhoven, A. Kuijer, K. Schreuder, S.G. Elias, P.J. van Diest, E. van der Wall, S. Siesling, T. van Dalen SUMMARY: A Netherlands Cancer Registry study correlated the increased use of MammaPrint led to decreased chemotherapy use, especially for LN+ Read More

ASCO June 5 2019: Race and response to neoadjuvant chemotherapy

AUTHORS: Raquel Nunes, Femke de Snoo, Lisette Stork-Sloots, Tina Treece, Christa Dreezen, William Audeh DESCRIPTION: Race and response to neoadjuvant chemotherapy according to MammaPrint risk African-American (AA) women with breast cancer have a less favorable prognosis, likely due to differences in tumor biology. The Neoadjuvant BReast Cancer Symphony Trial (NBRST, Read More

2019 ASCO FLEX Poster

AUTHORS: Gordan Srkalovic, Adam Brufsky, Jennifer Crozier, Mehran Habibi, Pat Whitworth, Charles Cox, Ian Grady, Nina D’Abreo, Sarah Untch, Erin Yoder, William Audeh, FLEX Investigators Group DESCRIPTION: Clinical Trial in Progress: The FLEX Big Data Platform Explores New Gene Expression Profiles and Investigator-Initiated Protocols in Early Stage Breast Cancer Genomic Read More